Scottsdale Institute Renews Bid for Drug Production Permit

2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment

Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.

2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas

The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.

2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation

Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.

2026-11572 — Ashley Vermillion, N.P.; Decision and Order

Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.

2026-11416 — Importer of Controlled Substances Application: CalCog Inc.

CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.

2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I

The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.

Previous: 2025-02738 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.

Patheon API Inc. wants to get official approval to make large amounts of certain controlled drugs. This affects anyone involved in drug manufacturing and regulation, as it could change who supplies these substances. Keep an eye out for updates, as this could impact drug availability and industry rules soon.

Next: 2025-02740 — Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals wants to get official approval to make large amounts of certain controlled drugs. This affects anyone involved in drug manufacturing and regulation, as Janssen aims to boost their production capabilities. Keep an eye out for updates on approvals and any new rules that might come with this change.